Literature DB >> 26439042

Insulin sensitivity indices: fasting versus glucose-stimulated ındices in pediatric non-alcoholic fatty liver disease.

B Ozhan1, B Ersoy, S Kiremitci, M Ozkol, F Taneli.   

Abstract

OBJECTIVE: We aimed to compare insulin sensitivity indices, fasting vs glucose stimulated, in children and adolescents with non-alcoholic fatty liver disease. PATIENTS AND METHODS: Two hundred-eleven obese children with median age of 11.24 ± 2.65 years were evaluated. After initial clinical and anthropometric examination, B-mode ultrasonography (USG) was performed and all subjects underwent Oral Glucose Tolerance Test (OGTT). Quantitative insulin sensitivity check index (QUICKI), homeostatic model assessment for insulin resistance (Homa-IR), the insulinogenic index (IGI), the Matsuda index, and the oral glucose insulin sensitivity (OGIS) model were used to determine peripheral insulin sensitivity.
RESULTS: 59.24% (68 boys, 57 girls) of obese children had NALFD. The prevalence of FLD in obese adolescents was significantly higher than in prepubertal children (65.8% vs. 51.5%). Fasting glucose, insulin, Homa-IR, QUICKI, and OGIS and Matsuda were significantly different between subjects with and without NALFD. Insulin and glucose indices were not found to be significantly different in the prepubertal group, whereas Homa-IR, QUICKI, Matsuda, and OGIS were significantly different in the pubertal group. Age, waist circumference, and OUICKI were found to be risk factors associated with the presence of NALFD in the logistic-regression analysis.
CONCLUSIONS: Age, waist circumference, and OUICKI were found to be risk factors associated with NALFD. As the value of QUICKI decreases, the probability of having steatosis increases. Although OGTT results gave the information about the glucose tolerance of a subject, indices derived from OGTT were not found to be superior to the traditional surrogates such as Homa-IR or QUICKI.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26439042

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  The triglycerides and glucose index is strongly associated with hepatic steatosis in children with overweight or obesity.

Authors:  Luis E Simental-Mendía; César Javier Ortega-Pacheco; Elvira García-Guerrero; María Alejandra Sicsik-Aragón; Fernando Guerrero-Romero; Gerardo Martínez-Aguilar
Journal:  Eur J Pediatr       Date:  2021-01-25       Impact factor: 3.183

2.  Effects of activated carbon N-acetylcysteine sustained-release microcapsule on dipeptidyl peptidase IV expression in young rats with non-alcoholic fatty liver disease.

Authors:  Hongping Zhou; Tingting Shi; Jun Yan; Xiaojin Chen; Li Liao; Shiyong Zhao; Hongying Fang; Rangxiao Zhuang
Journal:  Exp Ther Med       Date:  2017-09-19       Impact factor: 2.447

3.  Delay in glucose peak time during the oral glucose tolerance test as an indicator of insulin resistance and insulin secretion in type 2 diabetes patients.

Authors:  Xinlei Wang; Xiaoqin Zhao; Ranran Zhou; Yunjuan Gu; Xiaohui Zhu; Zhuqi Tang; Xinlu Yuan; Wei Chen; Rongping Zhang; Chen Qian; Shiwei Cui
Journal:  J Diabetes Investig       Date:  2018-04-20       Impact factor: 4.232

4.  Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease.

Authors:  Sara Carbajo-Pescador; David Porras; María Victoria García-Mediavilla; Susana Martínez-Flórez; María Juarez-Fernández; María José Cuevas; José Luis Mauriz; Javier González-Gallego; Esther Nistal; Sonia Sánchez-Campos
Journal:  Dis Model Mech       Date:  2019-04-30       Impact factor: 5.758

5.  Steroid metabolomic signature of liver disease in nonsyndromic childhood obesity.

Authors:  Aneta Gawlik; Michael Shmoish; Michaela F Hartmann; Stefan A Wudy; Zbigniew Olczak; Katarzyna Gruszczynska; Ze'ev Hochberg
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335

6.  Fasting Glucose State Determines Metabolic Response to Supplementation with Insoluble Cereal Fibre: A Secondary Analysis of the Optimal Fibre Trial (OptiFiT).

Authors:  Stefan Kabisch; Nina M T Meyer; Caroline Honsek; Christiana Gerbracht; Ulrike Dambeck; Margrit Kemper; Martin A Osterhoff; Andreas L Birkenfeld; Ayman M Arafat; Mads F Hjorth; Martin O Weickert; Andreas F H Pfeiffer
Journal:  Nutrients       Date:  2019-10-06       Impact factor: 5.717

Review 7.  The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population-A Review.

Authors:  Thomas Pixner; Nathalie Stummer; Anna Maria Schneider; Andreas Lukas; Karin Gramlinger; Valérie Julian; David Thivel; Katharina Mörwald; Katharina Maruszczak; Harald Mangge; Julian Gomahr; Daniel Weghuber; Dieter Furthner
Journal:  Life (Basel)       Date:  2022-06-05

Review 8.  A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence.

Authors:  Jonathan L Temple; Paul Cordero; Jiawei Li; Vi Nguyen; Jude A Oben
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

9.  Obesity Does Not Modulate the Glycometabolic Benefit of Insoluble Cereal Fibre in Subjects with Prediabetes-A Stratified Post Hoc Analysis of the Optimal Fibre Trial (OptiFiT).

Authors:  Stefan Kabisch; Nina Marie Tosca Meyer; Caroline Honsek; Christiana Gerbracht; Ulrike Dambeck; Margrit Kemper; Martin A Osterhoff; Andreas L Birkenfeld; Ayman M Arafat; Martin O Weickert; Andreas F H Pfeiffer
Journal:  Nutrients       Date:  2019-11-11       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.